| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccination | 27 | 2024 | 1123 | 3.380 |
Why?
|
| Rotavirus Infections | 17 | 2022 | 287 | 2.880 |
Why?
|
| Rotavirus Vaccines | 13 | 2022 | 67 | 2.860 |
Why?
|
| Influenza Vaccines | 10 | 2024 | 635 | 2.160 |
Why?
|
| Gastroenteritis | 12 | 2022 | 300 | 2.060 |
Why?
|
| Influenza, Human | 14 | 2024 | 925 | 2.010 |
Why?
|
| Immunization Programs | 5 | 2020 | 73 | 1.720 |
Why?
|
| Vaccines | 6 | 2023 | 389 | 1.580 |
Why?
|
| Immunization | 6 | 2021 | 397 | 1.380 |
Why?
|
| Rotavirus | 10 | 2022 | 377 | 1.380 |
Why?
|
| Respiratory Tract Infections | 8 | 2024 | 437 | 1.230 |
Why?
|
| Hospitalization | 25 | 2024 | 2083 | 1.180 |
Why?
|
| Mothers | 5 | 2024 | 410 | 1.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2021 | 1209 | 1.150 |
Why?
|
| Autism Spectrum Disorder | 3 | 2021 | 363 | 1.030 |
Why?
|
| Parents | 8 | 2021 | 998 | 0.940 |
Why?
|
| Infant | 43 | 2024 | 13310 | 0.910 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 573 | 0.880 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 5 | 2024 | 242 | 0.880 |
Why?
|
| Papillomavirus Vaccines | 6 | 2021 | 195 | 0.870 |
Why?
|
| Pediatrics | 4 | 2019 | 1141 | 0.850 |
Why?
|
| Enterovirus Infections | 4 | 2024 | 47 | 0.800 |
Why?
|
| Child | 46 | 2024 | 29154 | 0.770 |
Why?
|
| Respiratory Syncytial Virus, Human | 4 | 2024 | 211 | 0.760 |
Why?
|
| Reminder Systems | 3 | 2016 | 83 | 0.720 |
Why?
|
| Texas | 16 | 2021 | 6311 | 0.710 |
Why?
|
| Reassortant Viruses | 3 | 2016 | 32 | 0.710 |
Why?
|
| Epidemiological Monitoring | 3 | 2018 | 73 | 0.700 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 860 | 0.690 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2024 | 427 | 0.650 |
Why?
|
| Arbovirus Infections | 1 | 2018 | 29 | 0.650 |
Why?
|
| Population Surveillance | 5 | 2021 | 627 | 0.630 |
Why?
|
| Child, Preschool | 31 | 2024 | 16273 | 0.610 |
Why?
|
| Vaccination Refusal | 1 | 2017 | 17 | 0.610 |
Why?
|
| Viruses | 3 | 2024 | 159 | 0.600 |
Why?
|
| Fever | 3 | 2024 | 497 | 0.600 |
Why?
|
| Autistic Disorder | 1 | 2020 | 319 | 0.590 |
Why?
|
| Fathers | 1 | 2017 | 68 | 0.590 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 252 | 0.570 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 5 | 2023 | 152 | 0.530 |
Why?
|
| Hospitals, Pediatric | 5 | 2024 | 773 | 0.530 |
Why?
|
| Immunization Schedule | 4 | 2019 | 117 | 0.510 |
Why?
|
| Database Management Systems | 1 | 2014 | 63 | 0.500 |
Why?
|
| Seasons | 7 | 2024 | 340 | 0.480 |
Why?
|
| Case-Control Studies | 16 | 2024 | 6100 | 0.480 |
Why?
|
| Attitude to Health | 1 | 2017 | 465 | 0.480 |
Why?
|
| Humans | 84 | 2024 | 261506 | 0.470 |
Why?
|
| Enterovirus | 2 | 2024 | 63 | 0.450 |
Why?
|
| United States | 28 | 2024 | 15433 | 0.440 |
Why?
|
| Mass Media | 1 | 2013 | 36 | 0.440 |
Why?
|
| Health Education | 2 | 2013 | 309 | 0.440 |
Why?
|
| Social Media | 3 | 2021 | 203 | 0.440 |
Why?
|
| Metapneumovirus | 2 | 2022 | 58 | 0.420 |
Why?
|
| Adolescent | 22 | 2024 | 31252 | 0.410 |
Why?
|
| Forecasting | 1 | 2014 | 694 | 0.400 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 1320 | 0.400 |
Why?
|
| Infant, Newborn | 14 | 2024 | 8223 | 0.400 |
Why?
|
| Information Systems | 2 | 2010 | 54 | 0.390 |
Why?
|
| Vaccines, Attenuated | 8 | 2022 | 210 | 0.390 |
Why?
|
| Feces | 10 | 2021 | 770 | 0.390 |
Why?
|
| Enterovirus D, Human | 2 | 2021 | 8 | 0.380 |
Why?
|
| Infection Control | 1 | 2013 | 270 | 0.380 |
Why?
|
| Hospital Information Systems | 1 | 2010 | 46 | 0.370 |
Why?
|
| Coinfection | 3 | 2022 | 189 | 0.370 |
Why?
|
| Papillomavirus Infections | 4 | 2020 | 980 | 0.370 |
Why?
|
| Disease Outbreaks | 3 | 2021 | 415 | 0.350 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 761 | 0.330 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 355 | 0.330 |
Why?
|
| Access to Information | 1 | 2008 | 65 | 0.320 |
Why?
|
| Reimbursement Mechanisms | 1 | 2008 | 78 | 0.320 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 5687 | 0.310 |
Why?
|
| Peer Group | 1 | 2008 | 133 | 0.310 |
Why?
|
| Health Promotion | 2 | 2008 | 502 | 0.300 |
Why?
|
| Informed Consent | 1 | 2010 | 419 | 0.300 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 175 | 0.290 |
Why?
|
| Education, Medical, Continuing | 1 | 2008 | 251 | 0.280 |
Why?
|
| Genotype | 8 | 2021 | 4109 | 0.280 |
Why?
|
| Insurance Coverage | 1 | 2008 | 256 | 0.280 |
Why?
|
| Prospective Studies | 12 | 2024 | 12873 | 0.280 |
Why?
|
| Disasters | 1 | 2007 | 107 | 0.270 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2022 | 419 | 0.260 |
Why?
|
| Fucosyltransferases | 2 | 2015 | 76 | 0.260 |
Why?
|
| Caliciviridae Infections | 2 | 2020 | 279 | 0.260 |
Why?
|
| Male | 32 | 2023 | 123000 | 0.260 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 945 | 0.250 |
Why?
|
| Female | 34 | 2024 | 141928 | 0.250 |
Why?
|
| Norovirus | 2 | 2020 | 287 | 0.250 |
Why?
|
| Emergency Service, Hospital | 5 | 2024 | 1148 | 0.250 |
Why?
|
| Picornaviridae Infections | 1 | 2024 | 57 | 0.230 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2024 | 55 | 0.230 |
Why?
|
| Electronic Health Records | 2 | 2023 | 929 | 0.230 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2024 | 171 | 0.220 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 50 | 0.220 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 748 | 0.210 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2022 | 48 | 0.210 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2021 | 4 | 0.210 |
Why?
|
| Turbinates | 1 | 2021 | 17 | 0.210 |
Why?
|
| Anti-Vaccination Movement | 1 | 2021 | 11 | 0.210 |
Why?
|
| Pediatricians | 1 | 2021 | 58 | 0.200 |
Why?
|
| Family Relations | 1 | 2021 | 88 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 4314 | 0.190 |
Why?
|
| RNA, Viral | 2 | 2021 | 671 | 0.190 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 63 | 0.190 |
Why?
|
| Dermatomyositis | 1 | 2000 | 34 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 182 | 0.190 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2010 | 42 | 0.180 |
Why?
|
| Mobile Health Units | 1 | 2020 | 34 | 0.180 |
Why?
|
| Physicians | 1 | 2008 | 882 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2022 | 332 | 0.180 |
Why?
|
| Semantics | 1 | 2020 | 58 | 0.180 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2020 | 86 | 0.180 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 83 | 0.180 |
Why?
|
| Muscle Weakness | 1 | 2000 | 116 | 0.180 |
Why?
|
| Bacteriophages | 1 | 2020 | 71 | 0.180 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2019 | 17 | 0.170 |
Why?
|
| Spain | 1 | 2019 | 113 | 0.170 |
Why?
|
| Family Health | 1 | 2020 | 325 | 0.170 |
Why?
|
| Urban Population | 2 | 2010 | 269 | 0.170 |
Why?
|
| Vaccination Coverage | 1 | 2019 | 37 | 0.170 |
Why?
|
| Communicable Diseases, Imported | 1 | 2018 | 5 | 0.170 |
Why?
|
| Virus Diseases | 1 | 2022 | 398 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.160 |
Why?
|
| Antigens, Viral | 3 | 2024 | 471 | 0.160 |
Why?
|
| Chikungunya Fever | 1 | 2018 | 24 | 0.160 |
Why?
|
| Outpatients | 1 | 2021 | 462 | 0.160 |
Why?
|
| Exanthema | 1 | 2000 | 211 | 0.160 |
Why?
|
| Computers, Handheld | 1 | 2019 | 69 | 0.160 |
Why?
|
| Bites and Stings | 1 | 2018 | 44 | 0.160 |
Why?
|
| Phylogeny | 2 | 2021 | 826 | 0.160 |
Why?
|
| Information Dissemination | 1 | 2021 | 272 | 0.160 |
Why?
|
| Pandemics | 3 | 2023 | 1559 | 0.160 |
Why?
|
| Online Systems | 1 | 2017 | 27 | 0.150 |
Why?
|
| Pregnancy, High-Risk | 1 | 2017 | 49 | 0.150 |
Why?
|
| Communication | 2 | 2021 | 876 | 0.150 |
Why?
|
| Dengue | 1 | 2018 | 109 | 0.150 |
Why?
|
| Pregnancy | 5 | 2024 | 7573 | 0.150 |
Why?
|
| Community Participation | 1 | 2017 | 53 | 0.150 |
Why?
|
| Acute Disease | 2 | 2022 | 2422 | 0.150 |
Why?
|
| Travel | 1 | 2018 | 190 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2008 | 430 | 0.140 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 16 | 0.140 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 674 | 0.140 |
Why?
|
| Haemophilus Vaccines | 1 | 2016 | 40 | 0.140 |
Why?
|
| Chickenpox Vaccine | 1 | 2016 | 18 | 0.140 |
Why?
|
| Pregnant Women | 1 | 2017 | 162 | 0.140 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2016 | 16 | 0.140 |
Why?
|
| West Nile Fever | 1 | 2018 | 151 | 0.140 |
Why?
|
| Infectious Disease Medicine | 1 | 2016 | 20 | 0.140 |
Why?
|
| Knowledge Bases | 1 | 2016 | 41 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2021 | 717 | 0.140 |
Why?
|
| Hepatitis B Vaccines | 1 | 2016 | 51 | 0.140 |
Why?
|
| Motivation | 1 | 2019 | 499 | 0.130 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2016 | 37 | 0.130 |
Why?
|
| Genome, Viral | 1 | 2016 | 155 | 0.130 |
Why?
|
| Young Adult | 3 | 2019 | 21445 | 0.130 |
Why?
|
| Computer-Assisted Instruction | 1 | 2016 | 81 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Software Design | 1 | 2014 | 40 | 0.130 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 163 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 429 | 0.130 |
Why?
|
| Models, Organizational | 1 | 2014 | 76 | 0.120 |
Why?
|
| Adult | 7 | 2024 | 77950 | 0.120 |
Why?
|
| Prevalence | 2 | 2021 | 3260 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2015 | 445 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2020 | 497 | 0.110 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2014 | 220 | 0.110 |
Why?
|
| Rhinovirus | 2 | 2023 | 94 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3251 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 244 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.110 |
Why?
|
| Patient Acuity | 2 | 2022 | 72 | 0.100 |
Why?
|
| Influenza B virus | 2 | 2022 | 127 | 0.100 |
Why?
|
| Child, Hospitalized | 2 | 2022 | 62 | 0.100 |
Why?
|
| Registries | 2 | 2010 | 2170 | 0.100 |
Why?
|
| Presumed Consent | 1 | 2010 | 4 | 0.100 |
Why?
|
| Hospitals, Maternity | 1 | 2010 | 9 | 0.100 |
Why?
|
| Serum | 1 | 2010 | 68 | 0.090 |
Why?
|
| Logistic Models | 1 | 2017 | 3441 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 306 | 0.090 |
Why?
|
| Urban Health Services | 1 | 2008 | 37 | 0.080 |
Why?
|
| Family Practice | 1 | 2008 | 125 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 485 | 0.080 |
Why?
|
| Age Distribution | 1 | 2010 | 698 | 0.080 |
Why?
|
| Public Health Practice | 1 | 2007 | 22 | 0.080 |
Why?
|
| Louisiana | 1 | 2007 | 139 | 0.080 |
Why?
|
| Private Practice | 1 | 2007 | 31 | 0.070 |
Why?
|
| Cost of Illness | 2 | 2020 | 498 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2008 | 250 | 0.070 |
Why?
|
| Age Factors | 2 | 2019 | 5377 | 0.070 |
Why?
|
| User-Computer Interface | 2 | 2019 | 286 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 5539 | 0.060 |
Why?
|
| RNA, Messenger, Stored | 1 | 2023 | 6 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 1217 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2023 | 6150 | 0.060 |
Why?
|
| Health Personnel | 1 | 2008 | 625 | 0.060 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2022 | 49 | 0.050 |
Why?
|
| Health Behavior | 1 | 2007 | 603 | 0.050 |
Why?
|
| Coronavirus | 1 | 2022 | 40 | 0.050 |
Why?
|
| Paramyxoviridae Infections | 1 | 2022 | 86 | 0.050 |
Why?
|
| Oseltamivir | 1 | 2021 | 33 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 110 | 0.050 |
Why?
|
| Life Support Care | 1 | 2022 | 50 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 172 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 1489 | 0.050 |
Why?
|
| Social Networking | 1 | 2020 | 28 | 0.050 |
Why?
|
| Dermatitis | 1 | 2000 | 60 | 0.050 |
Why?
|
| Transients and Migrants | 1 | 2020 | 27 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2024 | 9244 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 203 | 0.040 |
Why?
|
| Public Health | 1 | 2021 | 299 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 319 | 0.040 |
Why?
|
| Oxygen | 1 | 2022 | 754 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 289 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2019 | 102 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2007 | 1303 | 0.040 |
Why?
|
| Automation | 1 | 2017 | 151 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2022 | 1459 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 717 | 0.040 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 364 | 0.040 |
Why?
|
| Critical Illness | 1 | 2022 | 714 | 0.040 |
Why?
|
| Poverty | 1 | 2020 | 471 | 0.040 |
Why?
|
| Weight Loss | 1 | 2000 | 627 | 0.030 |
Why?
|
| Consumer Health Information | 1 | 2016 | 52 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 2352 | 0.030 |
Why?
|
| Saliva | 1 | 2015 | 231 | 0.030 |
Why?
|
| Cattle | 1 | 2016 | 783 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 1230 | 0.030 |
Why?
|
| Fatigue | 1 | 2000 | 1239 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 3639 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 678 | 0.030 |
Why?
|
| Premature Birth | 1 | 2019 | 407 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 1163 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 706 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 429 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2884 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4367 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2013 | 554 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6089 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2021 | 32848 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 12926 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 14889 | 0.020 |
Why?
|
| Teaching | 1 | 2007 | 243 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 59536 | 0.010 |
Why?
|
| Risk Factors | 1 | 2020 | 17523 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 4971 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 4892 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 2803 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 37905 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.010 |
Why?
|